Trial Profile

An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms ELOQUENT-3
Sponsors Bristol-Myers Squibb

Most Recent Events

19 Dec 2022 This trial has been completed in Italy, according to the European Clinical Trials Database record
12 Aug 2022 Results of final overall survival analysis published in the Journal of Clinical Oncology
11 Jan 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com